医学
结直肠癌
细胞因子诱导的杀伤细胞
免疫疗法
临床试验
细胞疗法
肿瘤科
癌症
重症监护医学
内科学
免疫学
细胞
免疫系统
CD8型
CD3型
生物
遗传学
作者
Celine Man Ying Li,Runhao Li,Paul A. Drew,Timothy Price,Eric A. Smith,Guy J. Maddern,Yoko Tomita,Kevin Fenix
标识
DOI:10.1016/j.ctrv.2023.102665
摘要
Colorectal cancer (CRC) remains a significant global health burden and is the second leading cause of cancerrelated death.Cytokine induced killer (CIK) cell therapy is an immunotherapy which has the potential to meet this need.Clinical trials of CIK cell therapy for the management of CRC have reported improved clinical outcomes.However, production and delivery protocols varied significantly, and many studies were reported only in Chinese language journals.Here we present the most comprehensive review of the clinical CIK cell therapy trials for CRC management to date.We accessed both English and Chinese language clinical studies, and summarise how CIK cell therapy has been implemented, from manufacturing to patient delivery.We discuss current challenges that impede wider adoption of CIK cell therapy in CRC management.
科研通智能强力驱动
Strongly Powered by AbleSci AI